BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 27919964)

  • 1. Implementing the Risk of Ovarian Malignancy Algorithm Adding Obesity as a Predictive Factor.
    Anastasi E; Capoccia D; Granato T; Silecchia G; Rizzello M; Porpora MG; Frati L; Angeloni A; Leonetti F
    Anticancer Res; 2016 Dec; 36(12):6425-6429. PubMed ID: 27919964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the association between 25-OH vitamin D levels and ROMA score in a population of obese women.
    Anastasi E; Capoccia D; Granato T; Viggiani V; Tartaglione S; Manganaro L; Angeloni A; Leonetti F
    J Biol Regul Homeost Agents; 2016; 30(4):1165-1171. PubMed ID: 28078870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
    Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
    Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 and ROMA index in Czech postmenopausal women.
    Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
    Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
    Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A
    Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey.
    Plotti F; Capriglione S; Scaletta G; Luvero D; Lopez S; Nastro FF; Terranova C; De Cicco Nardone C; Montera R; Angioli R
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():51-56. PubMed ID: 29660578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.
    Moore RG; Hawkins DM; Miller MC; Landrum LM; Gajewski W; Ball JJ; Allard WJ; Skates SJ
    Gynecol Oncol; 2014 Dec; 135(3):547-51. PubMed ID: 25449569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
    Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
    J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of obesity on survival in epithelial ovarian cancer.
    Pavelka JC; Brown RS; Karlan BY; Cass I; Leuchter RS; Lagasse LD; Li AJ
    Cancer; 2006 Oct; 107(7):1520-4. PubMed ID: 16941453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women.
    Rodriguez C; Calle EE; Fakhrabadi-Shokoohi D; Jacobs EJ; Thun MJ
    Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):822-8. PubMed ID: 12223425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.